Perspective Therapeutics, Inc. Common Stock CATX 深 沪
已收盘 09-05 16:00:00 美东时间
3.46
-0.080
-2.26%
华盛通- 最 高3.85
- 今 开3.54
- 成交量 200.55万股
- 最 低 3.44
- 昨 收 3.54
- 总市值 2.57亿
- 52周最高 15.275
- 市盈率 静 --
- 换手率 2.70%
- 52周最低 1.60
- 委 比 0.00%
- 总股本 7422.83万
- 历史最高 37.90
- 量 比 4.04
- 振 幅 11.58%
- 历史最低 1.60
- 每 手 1
- 风险率 4.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Perspective Therapeutics Names Joel Sendek CFO As Juan Graham Departs
Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as
09-04 19:24
Perspective Therapeutics Appoints Maya Martinez-Davis to Board
The latest announcement is out from Perspective Therapeutics ( ($CATX) ). On Se...
09-03 19:29
Perspective Therapeutics to Participate in Upcoming September Conferences
Perspective Therapeutics, Inc. announced that senior leadership will participate in upcoming conferences including the Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, and OPCO Targeted Radiopharmaceutical Therapies in Oncology Summit. The company, specializing in radiopharmaceutical treatments for cancers, utilizes the alpha-emitting isotope 212Pb to target cancer cells. Their "theranostic" approach combines imag...
08-26 11:00
Perspective Therapeutics Q2 EPS $(0.30), Inline, Sales $290.000K Beat $154.455K Estimate
Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.30) per share which met the analyst consensus estimate. This is a 76.47 percent decrease over losses of $(0.17) per share from the same period last
08-13 18:47
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ:EVO) is projected to repor...
08-13 16:32
A Look Ahead: Perspective Therapeutics's Earnings Forecast
Perspective Therapeutics (AMEX:CATX) is preparing to release its quarterly earn...
08-13 04:02
Perspective Therapeutics Updates Radiopharmaceutical Platform Presentation
Perspective Therapeutics ( ($CATX) ) just unveiled an announcement. On August 1...
08-02 04:29
Perspective Therapeutics To Present Updated [212Pb]VMT-α-NET Cancer Therapy Data At ESMO Congress 2025
Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the
07-25 00:46
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025
Perspective Therapeutics announced updated data on their [212Pb]VMT-α-NET program for advanced somatostatin receptor 2 positive neuroendocrine tumors, accepted for presentation at the ESMO Congress 2025 in Berlin. The presentation, titled "Safety and efficacy of [212Pb]VMT-α-NET in SSTR2+ NETs," will feature mature safety and preliminary efficacy results from 44 patients in dose-finding cohorts 1 and 2. The therapy uses 212Pb alpha particles to t...
07-24 16:45
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 23, 2025 /PRNewswire/ -- USA News Group News Commentary – Cancer diagnoses are climbing fastest...
07-23 21:26
